Aptamer-Functionalized Dendrimer Delivery of Plasmid-Encoding lncRNA MEG3 Enhances Gene Therapy in Castration-Resistant Prostate Cancer
Zongguang Tai,1,2,* Jinyuan Ma,1,* Jianing Ding,1,* Huijun Pan,1 Rongrong Chai,1 Congcong Zhu,1 Zhen Cui,1 Zhongjian Chen,1 Quangang Zhu1 1Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, People’s Republic of China; 2Department of Pharmacy, Changhai Ho...
Guardado en:
Autores principales: | Tai Z, Ma J, Ding J, Pan H, Chai R, Zhu C, Cui Z, Chen Z, Zhu Q |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b1336bbd2bec4814b2107a3f7d27965e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions
por: Caffo O, et al.
Publicado: (2016) -
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
por: Nikolai A. Ognerubov
Publicado: (2021) -
lncRNA MEG8 Upregulates miR-770-5p Through Methylation and Promotes Cell Apoptosis in Diabetic Nephropathy
por: Zhang J, et al.
Publicado: (2020) -
Avances en el tratamiento de cáncer de próstata resistente a la castración: énfasis en nuevas terapias hormonales
por: Berlin,Alejandro, et al.
Publicado: (2015) -
An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer
por: Josephina P. M. Vrouwe, et al.
Publicado: (2021)